BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Munabi NC, England RW, Edwards AK, Kitajewski AA, Tan QK, Weinstein A, Kung JE, Wilcox M, Kitajewski JK, Shawber CJ, Wu JK. Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation. Stem Cells Transl Med 2016;5:45-55. [PMID: 26574555 DOI: 10.5966/sctm.2015-0076] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhao F, Yang X, Xu G, Bi J, Lv R, Huo R. Propranolol suppresses HUVEC viability, migration, VEGF expression, and promotes apoptosis by downregulation of miR-4295. J Cell Biochem 2019;120:6614-23. [PMID: 30368887 DOI: 10.1002/jcb.27957] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
2 Cuesta AM, Albiñana V, Gallardo-Vara E, Recio-Poveda L, de Rojas-P I, de Las Heras KVG, Aguirre DT, Botella LM. The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease. Sci Rep 2019;9:10062. [PMID: 31296894 DOI: 10.1038/s41598-019-46448-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 De Giorgi V, Geppetti P, Lupi C, Benemei S. The Role of β-Blockers in Melanoma. J Neuroimmune Pharmacol 2020;15:17-26. [PMID: 31482435 DOI: 10.1007/s11481-019-09876-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Ji Y, Chen S, Wang Q, Xiang B, Xu Z, Zhong L, Yang K, Lu G, Qiu L. Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management. Sci Rep 2018;8:4264. [PMID: 29523832 DOI: 10.1038/s41598-018-22787-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
5 Edwards AK, Glithero K, Grzesik P, Kitajewski AA, Munabi NC, Hardy K, Tan QK, Schonning M, Kangsamaksin T, Kitajewski JK, Shawber CJ, Wu JK. NOTCH3 regulates stem-to-mural cell differentiation in infantile hemangioma. JCI Insight 2017;2:93764. [PMID: 29093274 DOI: 10.1172/jci.insight.93764] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
6 Li X, Chen Y, Fu C, Li H, Yang K, Bi J, Huo R. Characterization of epigenetic and transcriptional landscape in infantile hemangiomas with ATAC-seq and RNA-seq. Epigenomics 2020;12:893-905. [DOI: 10.2217/epi-2020-0060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Zhou C, Chen X, Zeng W, Peng C, Huang G, Li X, Ouyang Z, Luo Y, Xu X, Xu B, Wang W, He R, Zhang X, Zhang L, Liu J, Knepper TC, He Y, McLeod HL. Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway. Oncotarget 2016;7:68314-27. [PMID: 27582542 DOI: 10.18632/oncotarget.11599] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
8 Yao TH, Pataer P, Regmi KP, Gu XW, Li QY, Du JT, Ge SM, Tu JB. Propranolol induces hemangioma endothelial cell apoptosis via a p53BAX mediated pathway. Mol Med Rep. 2018;18:684-694. [PMID: 29767244 DOI: 10.3892/mmr.2018.9013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
9 Li H, Lou Y, Zhang R, Xie J, Cao D. Propranolol Accelerats Hemangioma Stem Cell Transformation Into Adipocyte. Ann Plast Surg 2019;83:e5-e13. [DOI: 10.1097/sap.0000000000002104] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Fernandez Faith E, Cordisco M. Unrelenting facial segmental hemangiomas: A case series of late growth and recurrent ulcerations. Pediatr Dermatol 2020;37:884-9. [DOI: 10.1111/pde.14253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Wu H, Wang X, Liang H, Zheng J, Huang S, Zhang D. Enhanced efficacy of propranolol therapy for infantile hemangiomas based on a mesoporous silica nanoplatform through mediating autophagy dysfunction. Acta Biomater 2020;107:272-85. [PMID: 32145394 DOI: 10.1016/j.actbio.2020.02.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Gomez-Acevedo H, Dai Y, Strub G, Shawber C, Wu JK, Richter GT. Identification of putative biomarkers for Infantile Hemangiomas and Propranolol treatment via data integration. Sci Rep 2020;10:3261. [PMID: 32094357 DOI: 10.1038/s41598-020-60025-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Weberpals J, Jansen L, Haefeli WE, Hoffmeister M, Wolkewitz M, Herk-Sukel MPPV, Vissers PAJ, Brenner H. Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study. Sci Rep 2017;7:2911. [PMID: 28588274 DOI: 10.1038/s41598-017-02913-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
14 Liu C, Zhao ZL, Wu HW, Zheng JW, Wang YA, Liu XJ, Fan XD. Effect of combined low-dose oral prednisone with beta-adrenergic receptor antagonists for refractory infantile hemangiomas: retrospective cohort study in 76 patients. Ann Transl Med 2019;7:750. [PMID: 32042766 DOI: 10.21037/atm.2019.11.94] [Reference Citation Analysis]
15 Dal Monte M, Calvani M, Cammalleri M, Favre C, Filippi L, Bagnoli P. β-Adrenoceptors as drug targets in melanoma: novel preclinical evidence for a role of β3 -adrenoceptors. Br J Pharmacol 2019;176:2496-508. [PMID: 30471093 DOI: 10.1111/bph.14552] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
16 Guo X, Zhu X, Gao J, Liu D, Dong C, Jin X. PLGA nanoparticles with CD133 aptamers for targeted delivery and sustained release of propranolol to hemangioma. Nanomedicine (Lond) 2017;12:2611-24. [PMID: 28960167 DOI: 10.2217/nnm-2017-0130] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
17 Montoya A, Varela-Ramirez A, Dickerson E, Pasquier E, Torabi A, Aguilera R, Nahleh Z, Bryan B. The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancer. Biomed J. 2019;42:155-165. [PMID: 31466709 DOI: 10.1016/j.bj.2019.02.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
18 Shakoor A, Wu JK, Muley A, Kitajewski C, McCarron JD, Shapiro-Franklin N, Corda R, Chrisomalis-Dring S, Chai PJ, Shawber CJ. Lymphatic Endothelial Cell Defects in Congenital Cardiac Patients With Postoperative Chylothorax. J Vasc Anom (Phila) 2021;2:e016. [PMID: 34590077 DOI: 10.1097/jova.0000000000000016] [Reference Citation Analysis]
19 Mong EF, Akat KM, Canfield J, Lockhart J, VanWye J, Matar A, Tsibris JCM, Wu JK, Tuschl T, Totary-Jain H. Modulation of LIN28B/Let-7 Signaling by Propranolol Contributes to Infantile Hemangioma Involution. Arterioscler Thromb Vasc Biol 2018;38:1321-32. [PMID: 29724816 DOI: 10.1161/ATVBAHA.118.310908] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
20 Albiñana V, Gallardo-Vara E, de Rojas-P I, Recio-Poveda L, Aguado T, Canto-Cano A, Aguirre DT, Serra MM, González-Peramato P, Martínez-Piñeiro L, Cuesta AM, Botella LM. Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel-Lindau Disease. J Clin Med 2020;9:E2740. [PMID: 32854260 DOI: 10.3390/jcm9092740] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Laakkonen JP, Lähteenvuo J, Jauhiainen S, Heikura T, Ylä-Herttuala S. Beyond endothelial cells: Vascular endothelial growth factors in heart, vascular anomalies and placenta. Vascul Pharmacol 2019;112:91-101. [PMID: 30342234 DOI: 10.1016/j.vph.2018.10.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
22 Zhang L, Wu HW, Yuan W, Zheng JW. Propranolol therapy for infantile hemangioma: our experience. Drug Des Devel Ther 2017;11:1401-8. [PMID: 28507428 DOI: 10.2147/DDDT.S134808] [Cited by in Crossref: 30] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
23 Oldenburg J, Malinverno M, Globisch MA, Maderna C, Corada M, Orsenigo F, Conze LL, Rorsman C, Sundell V, Arce M, Smith RO, Yau ACY, Billström GH, Mägi CÖ, Beznoussenko GV, Mironov AA, Fernando D, Daniel G, Olivari D, Fumagalli F, Lampugnani MG, Dejana E, Magnusson PU. Propranolol Reduces the Development of Lesions and Rescues Barrier Function in Cerebral Cavernous Malformations: A Preclinical Study. Stroke 2021;52:1418-27. [PMID: 33618555 DOI: 10.1161/STROKEAHA.120.029676] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
24 Moisan F, Oucherif S, Kaulanjan-Checkmodine P, Prey S, Rousseau B, Bonneu M, Claverol S, Gontier E, Lacomme S, Dousset L, Couffinhal T, Toutain J, Loot M, Cario-André M, Jullié ML, Léauté-Labrèze C, Taieb A, Rezvani HR. Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta blockade. Proc Natl Acad Sci U S A 2021;118:e2018690118. [PMID: 33558238 DOI: 10.1073/pnas.2018690118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
25 Blei F. Update March 2016. Lymphatic Research and Biology 2016;14:40-6. [DOI: 10.1089/lrb.2016.29000.fb] [Reference Citation Analysis]
26 Dai Y, Zheng H, Liu Z, Wang Y, Hu W. The flavonoid luteolin suppresses infantile hemangioma by targeting FZD6 in the Wnt pathway. Invest New Drugs 2021;39:775-84. [PMID: 33411210 DOI: 10.1007/s10637-020-01052-8] [Reference Citation Analysis]
27 Qiao J, Lin J, Zhang D, Li J, Chen C, Yu H, Li X, Fang B. Efficacy of Combined Topical Timolol and Oral Propranolol for Treating Infantile Hemangioma: A Meta-Analysis of Randomized Controlled Trials. Front Pharmacol 2020;11:554847. [PMID: 33132908 DOI: 10.3389/fphar.2020.554847] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
28 Shepard MJ, Bugarini A, Edwards NA, Lu J, Zhang Q, Wu T, Zhuang Z, Chittiboina P. Repurposing propranolol as an antitumor agent in von Hippel-Lindau disease. J Neurosurg 2018;:1-9. [PMID: 30497198 DOI: 10.3171/2018.5.JNS172879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
29 Albiñana V, Escribano RMJ, Soler I, Padial LR, Recio-Poveda L, Villar Gómez de Las Heras K, Botella LM. Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease. Orphanet J Rare Dis 2017;12:122. [PMID: 28662711 DOI: 10.1186/s13023-017-0664-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
30 Kim KM, Min DH, Jung HL, Shim JW, Kim DS, Shim JY, Park MS, Park HJ, Lee SY. Propranolol as a First-line Treatment for Pediatric Hemangioma: Outcome of a Single Institution Over One Year. Clin Pediatr Hematol Oncol 2016;23:97-104. [DOI: 10.15264/cpho.2016.23.2.97] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 Phillips RJ, Crock CM, Penington AJ, Bekhor PS. Prolonged tumour growth after treatment of infantile haemangioma with propranolol. Medical Journal of Australia 2017;206:131-131. [DOI: 10.5694/mja16.00846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
32 Keller RG, Stevens S, Hochman M. Modern Management of Nasal Hemangiomas. JAMA Facial Plast Surg 2017;19:327-32. [PMID: 28494055 DOI: 10.1001/jamafacial.2017.0197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Lee JC, Modiri O, England RW, Shawber CJ, Wu JK. Propranolol Therapy in Infantile Hemangioma: It Is Not Just About the Beta. Plast Reconstr Surg 2021;147:875-85. [PMID: 33776033 DOI: 10.1097/PRS.0000000000007699] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Zhao ZL, Liu C, Wang QZ, Wu HW, Zheng JW. Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients. Ann Transl Med 2021;9:116. [PMID: 33569418 DOI: 10.21037/atm-20-5359] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Fu C, Yang K, Zou Y, Huo R. Identification of Key microRNAs and Genes in Infantile Hemangiomas. Front Genet 2022;13:766561. [DOI: 10.3389/fgene.2022.766561] [Reference Citation Analysis]